Reported Earlier, CDC Recommends Merck's CAPVAXIVE For Adults 50+, Expanding Protection Against Invasive Pneumococcal Disease
Portfolio Pulse from Benzinga Newsdesk
The CDC has recommended Merck's CAPVAXIVE vaccine for adults aged 50 and older, expanding protection against invasive pneumococcal disease. This recommendation lowers the age for vaccination from 65 to 50 years. CAPVAXIVE covers 84% of disease-causing serotypes, compared to 52% by PCV20.
October 24, 2024 | 6:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The CDC's recommendation of Merck's CAPVAXIVE for adults 50+ could enhance Merck's market position in the pneumococcal vaccine segment, as CAPVAXIVE covers a higher percentage of serotypes compared to PCV20.
The CDC's recommendation significantly expands the potential market for CAPVAXIVE by lowering the vaccination age from 65 to 50. This could lead to increased sales and market share for Merck, as CAPVAXIVE offers broader protection compared to its competitor, PCV20.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90